Friendswood, TX, United States
Friendswood, TX, United States

Time filter

Source Type

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from studies evaluating clinical experience with gene expression profile (GEP) tests DecisionDx®-Melanoma and DecisionDx®-UM. In the studies, both GEP tests demonstrated a high technical success rate with robust, reproducible and reliable performance. The data were presented in poster sessions at the Association for Molecular Pathology


FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Derek Maetzold, President and CEO, will be presenting at the Canaccord Genuity 2016 Medical Technology & Diagnostics Forum today, Thursday, November 17th, 2016 at 1:40 p.m. EST in New York. About Castle BiosciencesCastle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best pos


News Article | November 22, 2016
Site: www.businesswire.com

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Derek Maetzold, President and CEO, will be presenting at the Piper Jaffray 28th Annual Healthcare Conference on Tuesday, November 29th, 2016 at 4:50 p.m. EST in New York. About Castle Biosciences Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about


The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set.


Patent
Castle Biosciences | Date: 2014-02-28

The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set.


Patent
Indiana University and Castle Biosciences | Date: 2013-06-22

Biomarkers are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer. In addition, kits are provided for measuring expression levels or the presence of the biomarkers associated with thymic cancer for detecting, diagnosing and prognosing thymic cancer. Furthermore, methods are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer via the biomarkers.


The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set.


FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the clinical impact of its gene expression profile (GEP) test DecisionDx®-Melanoma on patient management decisions. The test uses tumor biology to provide an individual risk of recurrence in cutaneous (skin) melanoma patients. The data were presented in a poster session at the Society for Melanoma Research 2016


FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, today appointed Patrick Hall, D.Ph., to the newly created role of Executive Director, Medical Affairs and announced the promotion of Robert W. Cook, Ph.D. The Company also announced the expansion of its sales force to meet the increasing demand among dermatologists, surgeons, oncologists and patients for its DecisionDx™-Melanoma diagnostic test services for cutaneous melanoma (see www.SkinMelanoma.com for further information). Dr. Hall will oversee the development of Medical Affairs strategies and programs at Castle Biosciences. He joins the Company with 27 years of industry experience in various roles in molecular diagnostics, bio-oncology, pharmaceutical sales and operations. Dr. Hall spent more than 11 years at Genomic Health, Inc., most recently as Director of Genomic Science Liaisons, where he oversaw the medical affairs activities of its breast, colon and prostate cancer assays. Previously, he served as Medical Science Liaison at Genentech, where he oversaw over 25 investigator-sponsored studies and physician-initiated trials for oncology products. In addition to this appointment, the Company announced the promotion of Robert W. Cook, Ph.D., who has served as Senior Scientist since 2011, to the newly created position of Executive Director, Research and Development. Dr. Cook joined Castle Biosciences in early 2011 as its first R&D employee. He oversees R&D activities including assay discovery, development and validation. In his four years at Castle Biosciences, Dr. Cook has co-invented several technologies including the DecisionDx-Melanoma test. Prior to completing a post-doctoral assignment at Baylor College of Medicine, Dr. Cook received his Ph.D. in biochemistry, molecular and cellular biology from Northwestern University. Dr. Cook spent five years at Gen-Probe designing diagnostic assays using nucleic acid amplification technology prior to pursuit of his Ph.D. “The addition of Patrick Hall to our management team, the recognition of Bob Cook’s contribution and the doubling of our sales force prepares the company to meet the growing adoption of our molecular diagnostic tools to improve patient care,” said Derek Maetzold, President and CEO of Castle Biosciences. Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow-up care based on the individual molecular signature of their tumor. The Company currently offers tests for patients with uveal melanoma (DecisionDx™-UM), cutaneous melanoma (DecisionDx™-Melanoma) and esophageal cancer (DecisionDx™-EC), among others. Castle Biosciences is based in Friendswood, TX (Houston), and has laboratory operations in Phoenix, AZ. More information can be found at www.castlebiosciences.com. DecisionDx™-UM, DecisionDx™-Melanoma and DecisionDx™-EC are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.


FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, today announced the publication of a study analyzing attitudes among thoracic surgeons toward the treatment of esophageal cancer (EC) with locoregional disease, demonstrating that Castle Biosciences’ predictive multi-analyte immunohistochemistry (IHC)–based test has a significant influence on physicians’ treatment decisions for patients living with this devastating form of cancer. The paper, titled “Intended Use for a Neoadjuvant Chemoradiation Response Prediction Test for Locally Advanced Esophageal Adenocarcinoma: A Survey Analysis of Thoracic Surgeons in the U.S.,” and published online by Current Medical Research & Opinion, demonstrated that Castle Biosciences’ test, known as DecisionDx-EC™, would influence physicians to adjust their treatment strategy based on the test’s ability to predict patients’ response or lack of response to neoadjuvant chemoradiotherapy (neoCTRT). Nearly twice as many surgeons stated an intention to change their treatment strategy for patients predicted to be resistant to neoCTRT compared to patients predicted to completely respond to neoCTRT, according to the survey. “The survey shows that most physicians treating esophageal cancer will make adjustments to treatment plans when it appears that current standard therapies will not be effective for an individual patient,” said Derek Maetzold, President and CEO of Castle Biosciences. “The DecisionDx-EC test gives physicians a guide for treating this disease in an evidence-based manner.” The survey assessed responses from 57 thoracic surgeons who were provided with a questionnaire about the current clinical management of locally advanced EC, and their intention to change their treatment strategy if the test predicts that a patient will experience either pathological complete response (pathCR) or is found to be extremely resistant to neoCTRT. Nearly all respondents stated that they administer neoCTRT followed by surgery to treat locally-advanced EC. Nearly two-thirds of the respondents said they would be willing to adjust their treatment approach for patients predicted to be resistant to neoCTRT. One out of four respondents who were willing to adjust treatment for a patient who is predicted to be resistant to CTRT chose to avoid CTRT and instead would move those patients directly to surgery. Additionally, approximately one-third of respondents currently prescribing neoCTRT acknowledged that a pathCR prediction provided by Castle’s test would change their treatment strategy. While the authors acknowledge the limitations of the survey—mainly that it addresses the attitudes of surgical oncologists while the decisions regarding treatment of esophageal cancer are generally made by a multidisciplinary team—the results strongly suggest that use of the IHC-based predictive test is of great interest to the physicians, and would likely contribute to more individualized treatment for patients with distinct sensitivity to neoCTRT. More information about the study can be found at: http://informahealthcare.com/doi/abs/10.1185/03007995.2015.1025730 The test, a three-protein biomarker assay, was discovered by researchers at the University of Texas MD Anderson Cancer Center and licensed to Castle Biosciences. Pre-treatment tumor biopsies were used to evaluate resistance (exCTRT) or responsiveness to (non-exCTRT) standard pre-surgical CTRT regimens under CAP-accredited, CLIA-certified laboratory protocols. According to validation studies published last month in Gastrointestinal Cancers: Target and Therapies, the test can reliably differentiate patients who are complete or partial responders to chemoradiotherapy from those who are non-responders. An initial, single center clinical validation study of 167 patients achieved an area under the curve (AUC) of 0.96 and an overall accuracy of 90%. The esophagus carries food and liquid from the mouth to the stomach. There are two main types of esophageal cancer: adenocarcinoma and squamous cell carcinoma. The most common form of the disease in the U.S. is adenocarcinoma and is most prevalent in Caucasian men between the ages of 50 and 70. Esophageal adenocarcinoma, which is one of the fastest growing cancers in the country, has also been linked to obesity – perhaps related to chronic exposure to stomach acid. According to the National Cancer Institute, about 18,000 Americans were diagnosed with esophageal cancer in 2013. Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow-up care based on the individual molecular signature of their tumor. The Company currently offers tests for patients with uveal melanoma, cutaneous melanoma and esophageal cancer, among others. Castle Biosciences is based in Friendswood, TX (Houston), and has laboratory operations in Phoenix, AZ. More information can be found at www.castlebiosciences.com. DecisionDx-UM™, DecisionDx-Melanoma™ and DecisionDx-EC™ are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.

Loading Castle Biosciences collaborators
Loading Castle Biosciences collaborators